nodes	percent_of_prediction	percent_of_DWPC	metapath
Alprostadil—SLCO3A1—Methotrexate—lymphatic system cancer	0.533	0.765	CbGbCtD
Alprostadil—ABCC4—Methotrexate—lymphatic system cancer	0.164	0.235	CbGbCtD
Alprostadil—Electrocardiogram abnormal—Mitoxantrone—lymphatic system cancer	0.0026	0.0086	CcSEcCtD
Alprostadil—Diabetic—Methotrexate—lymphatic system cancer	0.00255	0.00841	CcSEcCtD
Alprostadil—Anuria—Methotrexate—lymphatic system cancer	0.00243	0.00803	CcSEcCtD
Alprostadil—Cardiac failure congestive—Fludarabine—lymphatic system cancer	0.0023	0.00758	CcSEcCtD
Alprostadil—Injection site pain—Carmustine—lymphatic system cancer	0.00225	0.00742	CcSEcCtD
Alprostadil—Haemoglobin—Mechlorethamine—lymphatic system cancer	0.00223	0.00737	CcSEcCtD
Alprostadil—Haemorrhage—Mechlorethamine—lymphatic system cancer	0.00222	0.00734	CcSEcCtD
Alprostadil—Fungal infection—Mitoxantrone—lymphatic system cancer	0.00221	0.00729	CcSEcCtD
Alprostadil—Numbness—Vincristine—lymphatic system cancer	0.00211	0.00698	CcSEcCtD
Alprostadil—Accidental injury—Carmustine—lymphatic system cancer	0.00207	0.00685	CcSEcCtD
Alprostadil—Wheezing—Bleomycin—lymphatic system cancer	0.00204	0.00674	CcSEcCtD
Alprostadil—Sensory loss—Vincristine—lymphatic system cancer	0.00202	0.00668	CcSEcCtD
Alprostadil—Injection site reaction—Carmustine—lymphatic system cancer	0.00183	0.00602	CcSEcCtD
Alprostadil—Sweating increased—Fludarabine—lymphatic system cancer	0.00175	0.00578	CcSEcCtD
Alprostadil—Bronchitis—Fludarabine—lymphatic system cancer	0.00173	0.00571	CcSEcCtD
Alprostadil—Hyperkalaemia—Mitoxantrone—lymphatic system cancer	0.00168	0.00553	CcSEcCtD
Alprostadil—Upper respiratory tract infection—Fludarabine—lymphatic system cancer	0.00167	0.00552	CcSEcCtD
Alprostadil—Injury—Bleomycin—lymphatic system cancer	0.00166	0.00548	CcSEcCtD
Alprostadil—Haemoglobin—Teniposide—lymphatic system cancer	0.00165	0.00544	CcSEcCtD
Alprostadil—Haemorrhage—Teniposide—lymphatic system cancer	0.00164	0.00541	CcSEcCtD
Alprostadil—Hyperglycaemia—Fludarabine—lymphatic system cancer	0.00162	0.00536	CcSEcCtD
Alprostadil—Abnormal vision—Carmustine—lymphatic system cancer	0.0016	0.00528	CcSEcCtD
Alprostadil—Sepsis—Carmustine—lymphatic system cancer	0.00159	0.00526	CcSEcCtD
Alprostadil—Acute coronary syndrome—Fludarabine—lymphatic system cancer	0.00158	0.00522	CcSEcCtD
Alprostadil—Renal failure—Fludarabine—lymphatic system cancer	0.00158	0.0052	CcSEcCtD
Alprostadil—Myocardial infarction—Fludarabine—lymphatic system cancer	0.00157	0.00519	CcSEcCtD
Alprostadil—Infection—Mechlorethamine—lymphatic system cancer	0.00157	0.00518	CcSEcCtD
Alprostadil—Urinary tract infection—Fludarabine—lymphatic system cancer	0.00156	0.00515	CcSEcCtD
Alprostadil—Thrombocytopenia—Mechlorethamine—lymphatic system cancer	0.00155	0.0051	CcSEcCtD
Alprostadil—Ecchymosis—Mitoxantrone—lymphatic system cancer	0.00154	0.00509	CcSEcCtD
Alprostadil—Skin disorder—Mechlorethamine—lymphatic system cancer	0.00153	0.00506	CcSEcCtD
Alprostadil—Diabetes mellitus—Carmustine—lymphatic system cancer	0.00153	0.00506	CcSEcCtD
Alprostadil—Haematuria—Fludarabine—lymphatic system cancer	0.00153	0.00505	CcSEcCtD
Alprostadil—Flushing—Teniposide—lymphatic system cancer	0.00152	0.00502	CcSEcCtD
Alprostadil—Swelling—Carmustine—lymphatic system cancer	0.00151	0.00498	CcSEcCtD
Alprostadil—Sinusitis—Fludarabine—lymphatic system cancer	0.00151	0.00497	CcSEcCtD
Alprostadil—Sepsis—Mitoxantrone—lymphatic system cancer	0.00148	0.00489	CcSEcCtD
Alprostadil—Multiple fractures—Methotrexate—lymphatic system cancer	0.00146	0.00483	CcSEcCtD
Alprostadil—Fracture—Methotrexate—lymphatic system cancer	0.00146	0.00483	CcSEcCtD
Alprostadil—Injury—Carmustine—lymphatic system cancer	0.00145	0.00478	CcSEcCtD
Alprostadil—Haemoglobin—Fludarabine—lymphatic system cancer	0.00145	0.00478	CcSEcCtD
Alprostadil—Haemorrhage—Fludarabine—lymphatic system cancer	0.00144	0.00475	CcSEcCtD
Alprostadil—Hypoaesthesia—Fludarabine—lymphatic system cancer	0.00143	0.00473	CcSEcCtD
Alprostadil—Pharyngitis—Fludarabine—lymphatic system cancer	0.00143	0.00472	CcSEcCtD
Alprostadil—Swelling—Mitoxantrone—lymphatic system cancer	0.0014	0.00463	CcSEcCtD
Alprostadil—Visual impairment—Fludarabine—lymphatic system cancer	0.00139	0.00458	CcSEcCtD
Alprostadil—Cardiac failure congestive—Mitoxantrone—lymphatic system cancer	0.00137	0.00451	CcSEcCtD
Alprostadil—Anaemia—Teniposide—lymphatic system cancer	0.00132	0.00435	CcSEcCtD
Alprostadil—Pain in extremity—Vincristine—lymphatic system cancer	0.00127	0.0042	CcSEcCtD
Alprostadil—Hypertension—Teniposide—lymphatic system cancer	0.00123	0.00406	CcSEcCtD
Alprostadil—Burning sensation—Methotrexate—lymphatic system cancer	0.00122	0.00404	CcSEcCtD
Alprostadil—Hypokalaemia—Carmustine—lymphatic system cancer	0.00121	0.004	CcSEcCtD
Alprostadil—Cardiac arrest—Vincristine—lymphatic system cancer	0.00121	0.00399	CcSEcCtD
Alprostadil—Oedema—Teniposide—lymphatic system cancer	0.00116	0.00384	CcSEcCtD
Alprostadil—Blood creatinine increased—Mitoxantrone—lymphatic system cancer	0.00116	0.00383	CcSEcCtD
Alprostadil—Acute coronary syndrome—Bleomycin—lymphatic system cancer	0.00116	0.00383	CcSEcCtD
Alprostadil—Anaemia—Fludarabine—lymphatic system cancer	0.00116	0.00382	CcSEcCtD
Alprostadil—Infection—Teniposide—lymphatic system cancer	0.00116	0.00382	CcSEcCtD
Alprostadil—Myocardial infarction—Bleomycin—lymphatic system cancer	0.00115	0.00381	CcSEcCtD
Alprostadil—Thrombocytopenia—Teniposide—lymphatic system cancer	0.00114	0.00376	CcSEcCtD
Alprostadil—Tachycardia—Teniposide—lymphatic system cancer	0.00114	0.00375	CcSEcCtD
Alprostadil—Hypokalaemia—Mitoxantrone—lymphatic system cancer	0.00113	0.00372	CcSEcCtD
Alprostadil—Hyperhidrosis—Teniposide—lymphatic system cancer	0.00113	0.00371	CcSEcCtD
Alprostadil—Haematuria—Bleomycin—lymphatic system cancer	0.00112	0.0037	CcSEcCtD
Alprostadil—Pruritus—Mechlorethamine—lymphatic system cancer	0.00112	0.00369	CcSEcCtD
Alprostadil—Fungal infection—Methotrexate—lymphatic system cancer	0.0011	0.00363	CcSEcCtD
Alprostadil—Cough—Fludarabine—lymphatic system cancer	0.00109	0.00361	CcSEcCtD
Alprostadil—Hypotension—Teniposide—lymphatic system cancer	0.00109	0.00359	CcSEcCtD
Alprostadil—Convulsion—Fludarabine—lymphatic system cancer	0.00109	0.00359	CcSEcCtD
Alprostadil—Diarrhoea—Mechlorethamine—lymphatic system cancer	0.00108	0.00357	CcSEcCtD
Alprostadil—Haemoglobin—Bleomycin—lymphatic system cancer	0.00106	0.0035	CcSEcCtD
Alprostadil—Haemorrhage—Bleomycin—lymphatic system cancer	0.00106	0.00349	CcSEcCtD
Alprostadil—Discomfort—Fludarabine—lymphatic system cancer	0.00105	0.00348	CcSEcCtD
Alprostadil—Hypoaesthesia—Bleomycin—lymphatic system cancer	0.00105	0.00347	CcSEcCtD
Alprostadil—Sweating increased—Mitoxantrone—lymphatic system cancer	0.00104	0.00344	CcSEcCtD
Alprostadil—Hyperglycaemia—Carmustine—lymphatic system cancer	0.00104	0.00343	CcSEcCtD
Alprostadil—Oedema—Fludarabine—lymphatic system cancer	0.00102	0.00338	CcSEcCtD
Alprostadil—Infection—Fludarabine—lymphatic system cancer	0.00102	0.00335	CcSEcCtD
Alprostadil—Renal failure—Carmustine—lymphatic system cancer	0.00101	0.00333	CcSEcCtD
Alprostadil—Apnoea—Methotrexate—lymphatic system cancer	0.001	0.00331	CcSEcCtD
Alprostadil—Thrombocytopenia—Fludarabine—lymphatic system cancer	0.001	0.00331	CcSEcCtD
Alprostadil—Urinary tract infection—Carmustine—lymphatic system cancer	0.000998	0.00329	CcSEcCtD
Alprostadil—Rash—Mechlorethamine—lymphatic system cancer	0.000996	0.00329	CcSEcCtD
Alprostadil—Upper respiratory tract infection—Mitoxantrone—lymphatic system cancer	0.000995	0.00328	CcSEcCtD
Alprostadil—Dermatitis—Mechlorethamine—lymphatic system cancer	0.000995	0.00328	CcSEcCtD
Alprostadil—Hyperhidrosis—Fludarabine—lymphatic system cancer	0.000989	0.00326	CcSEcCtD
Alprostadil—Flushing—Bleomycin—lymphatic system cancer	0.00098	0.00323	CcSEcCtD
Alprostadil—Acute coronary syndrome—Vincristine—lymphatic system cancer	0.000966	0.00319	CcSEcCtD
Alprostadil—Hyperglycaemia—Mitoxantrone—lymphatic system cancer	0.000966	0.00319	CcSEcCtD
Alprostadil—Myocardial infarction—Vincristine—lymphatic system cancer	0.000961	0.00317	CcSEcCtD
Alprostadil—Feeling abnormal—Teniposide—lymphatic system cancer	0.00096	0.00317	CcSEcCtD
Alprostadil—Musculoskeletal stiffness—Methotrexate—lymphatic system cancer	0.000948	0.00313	CcSEcCtD
Alprostadil—Acute coronary syndrome—Mitoxantrone—lymphatic system cancer	0.000941	0.00311	CcSEcCtD
Alprostadil—Renal failure—Mitoxantrone—lymphatic system cancer	0.000939	0.0031	CcSEcCtD
Alprostadil—Nausea—Mechlorethamine—lymphatic system cancer	0.000938	0.0031	CcSEcCtD
Alprostadil—Myocardial infarction—Mitoxantrone—lymphatic system cancer	0.000936	0.00309	CcSEcCtD
Alprostadil—Hyperbilirubinaemia—Methotrexate—lymphatic system cancer	0.000935	0.00309	CcSEcCtD
Alprostadil—Urinary tract infection—Mitoxantrone—lymphatic system cancer	0.000928	0.00306	CcSEcCtD
Alprostadil—Haemoglobin—Carmustine—lymphatic system cancer	0.000927	0.00306	CcSEcCtD
Alprostadil—Haemorrhage—Carmustine—lymphatic system cancer	0.000922	0.00304	CcSEcCtD
Alprostadil—Abdominal pain—Teniposide—lymphatic system cancer	0.000921	0.00304	CcSEcCtD
Alprostadil—Body temperature increased—Teniposide—lymphatic system cancer	0.000921	0.00304	CcSEcCtD
Alprostadil—Erythema—Bleomycin—lymphatic system cancer	0.000919	0.00303	CcSEcCtD
Alprostadil—Hypoaesthesia—Carmustine—lymphatic system cancer	0.000917	0.00303	CcSEcCtD
Alprostadil—Haematuria—Mitoxantrone—lymphatic system cancer	0.00091	0.003	CcSEcCtD
Alprostadil—Dyspepsia—Fludarabine—lymphatic system cancer	0.000901	0.00297	CcSEcCtD
Alprostadil—Sinusitis—Mitoxantrone—lymphatic system cancer	0.000896	0.00296	CcSEcCtD
Alprostadil—Visual impairment—Carmustine—lymphatic system cancer	0.000888	0.00293	CcSEcCtD
Alprostadil—Hypoaesthesia—Vincristine—lymphatic system cancer	0.000876	0.00289	CcSEcCtD
Alprostadil—Pain—Fludarabine—lymphatic system cancer	0.000875	0.00289	CcSEcCtD
Alprostadil—Bradycardia—Mitoxantrone—lymphatic system cancer	0.000873	0.00288	CcSEcCtD
Alprostadil—Urethral disorder—Vincristine—lymphatic system cancer	0.000863	0.00285	CcSEcCtD
Alprostadil—Haemoglobin—Mitoxantrone—lymphatic system cancer	0.000861	0.00284	CcSEcCtD
Alprostadil—Rhinitis—Mitoxantrone—lymphatic system cancer	0.000859	0.00284	CcSEcCtD
Alprostadil—Haemorrhage—Mitoxantrone—lymphatic system cancer	0.000857	0.00283	CcSEcCtD
Alprostadil—Flushing—Carmustine—lymphatic system cancer	0.000856	0.00282	CcSEcCtD
Alprostadil—Pharyngitis—Mitoxantrone—lymphatic system cancer	0.000851	0.00281	CcSEcCtD
Alprostadil—Anaemia—Bleomycin—lymphatic system cancer	0.00085	0.0028	CcSEcCtD
Alprostadil—Feeling abnormal—Fludarabine—lymphatic system cancer	0.000843	0.00278	CcSEcCtD
Alprostadil—Asthenia—Teniposide—lymphatic system cancer	0.000835	0.00276	CcSEcCtD
Alprostadil—Pruritus—Teniposide—lymphatic system cancer	0.000824	0.00272	CcSEcCtD
Alprostadil—Body temperature increased—Fludarabine—lymphatic system cancer	0.000809	0.00267	CcSEcCtD
Alprostadil—Erythema—Carmustine—lymphatic system cancer	0.000803	0.00265	CcSEcCtD
Alprostadil—Cough—Bleomycin—lymphatic system cancer	0.000802	0.00265	CcSEcCtD
Alprostadil—Diarrhoea—Teniposide—lymphatic system cancer	0.000797	0.00263	CcSEcCtD
Alprostadil—Back pain—Carmustine—lymphatic system cancer	0.000776	0.00256	CcSEcCtD
Alprostadil—Discomfort—Bleomycin—lymphatic system cancer	0.000773	0.00255	CcSEcCtD
Alprostadil—Ecchymosis—Methotrexate—lymphatic system cancer	0.000769	0.00254	CcSEcCtD
Alprostadil—Oedema—Bleomycin—lymphatic system cancer	0.00075	0.00248	CcSEcCtD
Alprostadil—Erythema—Mitoxantrone—lymphatic system cancer	0.000746	0.00246	CcSEcCtD
Alprostadil—Infection—Bleomycin—lymphatic system cancer	0.000745	0.00246	CcSEcCtD
Alprostadil—Anaemia—Carmustine—lymphatic system cancer	0.000742	0.00245	CcSEcCtD
Alprostadil—Back pain—Vincristine—lymphatic system cancer	0.000741	0.00245	CcSEcCtD
Alprostadil—Sepsis—Methotrexate—lymphatic system cancer	0.000738	0.00243	CcSEcCtD
Alprostadil—Thrombocytopenia—Bleomycin—lymphatic system cancer	0.000735	0.00242	CcSEcCtD
Alprostadil—Asthenia—Fludarabine—lymphatic system cancer	0.000734	0.00242	CcSEcCtD
Alprostadil—Rash—Teniposide—lymphatic system cancer	0.000734	0.00242	CcSEcCtD
Alprostadil—Dermatitis—Teniposide—lymphatic system cancer	0.000734	0.00242	CcSEcCtD
Alprostadil—Headache—Teniposide—lymphatic system cancer	0.00073	0.00241	CcSEcCtD
Alprostadil—Pruritus—Fludarabine—lymphatic system cancer	0.000724	0.00239	CcSEcCtD
Alprostadil—Back pain—Mitoxantrone—lymphatic system cancer	0.000722	0.00238	CcSEcCtD
Alprostadil—Diabetes mellitus—Methotrexate—lymphatic system cancer	0.00071	0.00234	CcSEcCtD
Alprostadil—Anaemia—Vincristine—lymphatic system cancer	0.000708	0.00234	CcSEcCtD
Alprostadil—Hypotension—Bleomycin—lymphatic system cancer	0.000701	0.00231	CcSEcCtD
Alprostadil—Diarrhoea—Fludarabine—lymphatic system cancer	0.0007	0.00231	CcSEcCtD
Alprostadil—Convulsion—Carmustine—lymphatic system cancer	0.000695	0.00229	CcSEcCtD
Alprostadil—Hypertension—Carmustine—lymphatic system cancer	0.000693	0.00229	CcSEcCtD
Alprostadil—Nausea—Teniposide—lymphatic system cancer	0.000692	0.00228	CcSEcCtD
Alprostadil—Anaemia—Mitoxantrone—lymphatic system cancer	0.00069	0.00228	CcSEcCtD
Alprostadil—Convulsion—Vincristine—lymphatic system cancer	0.000664	0.00219	CcSEcCtD
Alprostadil—Hypertension—Vincristine—lymphatic system cancer	0.000661	0.00218	CcSEcCtD
Alprostadil—Oedema—Carmustine—lymphatic system cancer	0.000655	0.00216	CcSEcCtD
Alprostadil—Cough—Mitoxantrone—lymphatic system cancer	0.000651	0.00215	CcSEcCtD
Alprostadil—Infection—Carmustine—lymphatic system cancer	0.000651	0.00215	CcSEcCtD
Alprostadil—Convulsion—Mitoxantrone—lymphatic system cancer	0.000646	0.00213	CcSEcCtD
Alprostadil—Rash—Fludarabine—lymphatic system cancer	0.000645	0.00213	CcSEcCtD
Alprostadil—Dermatitis—Fludarabine—lymphatic system cancer	0.000645	0.00213	CcSEcCtD
Alprostadil—Hypertension—Mitoxantrone—lymphatic system cancer	0.000644	0.00213	CcSEcCtD
Alprostadil—Pain—Bleomycin—lymphatic system cancer	0.000642	0.00212	CcSEcCtD
Alprostadil—Thrombocytopenia—Carmustine—lymphatic system cancer	0.000641	0.00212	CcSEcCtD
Alprostadil—Headache—Fludarabine—lymphatic system cancer	0.000641	0.00212	CcSEcCtD
Alprostadil—Tachycardia—Carmustine—lymphatic system cancer	0.000639	0.00211	CcSEcCtD
Alprostadil—Lethargy—Methotrexate—lymphatic system cancer	0.00063	0.00208	CcSEcCtD
Alprostadil—Discomfort—Mitoxantrone—lymphatic system cancer	0.000628	0.00207	CcSEcCtD
Alprostadil—Oedema—Vincristine—lymphatic system cancer	0.000625	0.00206	CcSEcCtD
Alprostadil—Infection—Vincristine—lymphatic system cancer	0.000621	0.00205	CcSEcCtD
Alprostadil—Feeling abnormal—Bleomycin—lymphatic system cancer	0.000618	0.00204	CcSEcCtD
Alprostadil—Thrombocytopenia—Vincristine—lymphatic system cancer	0.000612	0.00202	CcSEcCtD
Alprostadil—Hypotension—Carmustine—lymphatic system cancer	0.000612	0.00202	CcSEcCtD
Alprostadil—Oedema—Mitoxantrone—lymphatic system cancer	0.000609	0.00201	CcSEcCtD
Alprostadil—Nausea—Fludarabine—lymphatic system cancer	0.000608	0.00201	CcSEcCtD
Alprostadil—Infection—Mitoxantrone—lymphatic system cancer	0.000605	0.002	CcSEcCtD
Alprostadil—Hyperhidrosis—Vincristine—lymphatic system cancer	0.000604	0.00199	CcSEcCtD
Alprostadil—Shock—Mitoxantrone—lymphatic system cancer	0.000599	0.00198	CcSEcCtD
Alprostadil—Thrombocytopenia—Mitoxantrone—lymphatic system cancer	0.000596	0.00197	CcSEcCtD
Alprostadil—Tachycardia—Mitoxantrone—lymphatic system cancer	0.000594	0.00196	CcSEcCtD
Alprostadil—Body temperature increased—Bleomycin—lymphatic system cancer	0.000593	0.00196	CcSEcCtD
Alprostadil—Skin disorder—Mitoxantrone—lymphatic system cancer	0.000591	0.00195	CcSEcCtD
Alprostadil—Hyperhidrosis—Mitoxantrone—lymphatic system cancer	0.000589	0.00194	CcSEcCtD
Alprostadil—Hypotension—Vincristine—lymphatic system cancer	0.000584	0.00193	CcSEcCtD
Alprostadil—Hypotension—Mitoxantrone—lymphatic system cancer	0.000569	0.00188	CcSEcCtD
Alprostadil—Pain—Carmustine—lymphatic system cancer	0.00056	0.00185	CcSEcCtD
Alprostadil—Feeling abnormal—Carmustine—lymphatic system cancer	0.00054	0.00178	CcSEcCtD
Alprostadil—Asthenia—Bleomycin—lymphatic system cancer	0.000538	0.00178	CcSEcCtD
Alprostadil—Dyspepsia—Mitoxantrone—lymphatic system cancer	0.000536	0.00177	CcSEcCtD
Alprostadil—Pain—Vincristine—lymphatic system cancer	0.000535	0.00176	CcSEcCtD
Alprostadil—Pruritus—Bleomycin—lymphatic system cancer	0.000531	0.00175	CcSEcCtD
Alprostadil—Pain—Mitoxantrone—lymphatic system cancer	0.000521	0.00172	CcSEcCtD
Alprostadil—Abdominal pain—Carmustine—lymphatic system cancer	0.000518	0.00171	CcSEcCtD
Alprostadil—Body temperature increased—Carmustine—lymphatic system cancer	0.000518	0.00171	CcSEcCtD
Alprostadil—Feeling abnormal—Mitoxantrone—lymphatic system cancer	0.000502	0.00166	CcSEcCtD
Alprostadil—Upper respiratory tract infection—Methotrexate—lymphatic system cancer	0.000496	0.00164	CcSEcCtD
Alprostadil—Body temperature increased—Vincristine—lymphatic system cancer	0.000494	0.00163	CcSEcCtD
Alprostadil—Abdominal pain—Vincristine—lymphatic system cancer	0.000494	0.00163	CcSEcCtD
Alprostadil—Abdominal pain—Mitoxantrone—lymphatic system cancer	0.000481	0.00159	CcSEcCtD
Alprostadil—Body temperature increased—Mitoxantrone—lymphatic system cancer	0.000481	0.00159	CcSEcCtD
Alprostadil—Rash—Bleomycin—lymphatic system cancer	0.000473	0.00156	CcSEcCtD
Alprostadil—Dermatitis—Bleomycin—lymphatic system cancer	0.000473	0.00156	CcSEcCtD
Alprostadil—Asthenia—Carmustine—lymphatic system cancer	0.00047	0.00155	CcSEcCtD
Alprostadil—Renal failure—Methotrexate—lymphatic system cancer	0.000468	0.00154	CcSEcCtD
Alprostadil—Haematuria—Methotrexate—lymphatic system cancer	0.000454	0.0015	CcSEcCtD
Alprostadil—Asthenia—Vincristine—lymphatic system cancer	0.000449	0.00148	CcSEcCtD
Alprostadil—Diarrhoea—Carmustine—lymphatic system cancer	0.000448	0.00148	CcSEcCtD
Alprostadil—Nausea—Bleomycin—lymphatic system cancer	0.000446	0.00147	CcSEcCtD
Alprostadil—Asthenia—Mitoxantrone—lymphatic system cancer	0.000437	0.00144	CcSEcCtD
Alprostadil—Dizziness—Carmustine—lymphatic system cancer	0.000433	0.00143	CcSEcCtD
Alprostadil—Haemoglobin—Methotrexate—lymphatic system cancer	0.000429	0.00142	CcSEcCtD
Alprostadil—Diarrhoea—Vincristine—lymphatic system cancer	0.000428	0.00141	CcSEcCtD
Alprostadil—Haemorrhage—Methotrexate—lymphatic system cancer	0.000427	0.00141	CcSEcCtD
Alprostadil—Pharyngitis—Methotrexate—lymphatic system cancer	0.000424	0.0014	CcSEcCtD
Alprostadil—Urethral disorder—Methotrexate—lymphatic system cancer	0.000419	0.00138	CcSEcCtD
Alprostadil—Diarrhoea—Mitoxantrone—lymphatic system cancer	0.000417	0.00137	CcSEcCtD
Alprostadil—Dizziness—Vincristine—lymphatic system cancer	0.000413	0.00136	CcSEcCtD
Alprostadil—Rash—Carmustine—lymphatic system cancer	0.000413	0.00136	CcSEcCtD
Alprostadil—Dermatitis—Carmustine—lymphatic system cancer	0.000413	0.00136	CcSEcCtD
Alprostadil—Visual impairment—Methotrexate—lymphatic system cancer	0.000412	0.00136	CcSEcCtD
Alprostadil—Headache—Carmustine—lymphatic system cancer	0.00041	0.00135	CcSEcCtD
Alprostadil—Rash—Vincristine—lymphatic system cancer	0.000394	0.0013	CcSEcCtD
Alprostadil—Dermatitis—Vincristine—lymphatic system cancer	0.000394	0.0013	CcSEcCtD
Alprostadil—Headache—Vincristine—lymphatic system cancer	0.000392	0.00129	CcSEcCtD
Alprostadil—Nausea—Carmustine—lymphatic system cancer	0.000389	0.00128	CcSEcCtD
Alprostadil—Rash—Mitoxantrone—lymphatic system cancer	0.000384	0.00127	CcSEcCtD
Alprostadil—Dermatitis—Mitoxantrone—lymphatic system cancer	0.000384	0.00127	CcSEcCtD
Alprostadil—Headache—Mitoxantrone—lymphatic system cancer	0.000381	0.00126	CcSEcCtD
Alprostadil—Erythema—Methotrexate—lymphatic system cancer	0.000372	0.00123	CcSEcCtD
Alprostadil—Nausea—Vincristine—lymphatic system cancer	0.000371	0.00123	CcSEcCtD
Alprostadil—Nausea—Mitoxantrone—lymphatic system cancer	0.000362	0.00119	CcSEcCtD
Alprostadil—Back pain—Methotrexate—lymphatic system cancer	0.00036	0.00119	CcSEcCtD
Alprostadil—Anaemia—Methotrexate—lymphatic system cancer	0.000344	0.00113	CcSEcCtD
Alprostadil—Cough—Methotrexate—lymphatic system cancer	0.000324	0.00107	CcSEcCtD
Alprostadil—Convulsion—Methotrexate—lymphatic system cancer	0.000322	0.00106	CcSEcCtD
Alprostadil—Discomfort—Methotrexate—lymphatic system cancer	0.000313	0.00103	CcSEcCtD
Alprostadil—Infection—Methotrexate—lymphatic system cancer	0.000301	0.000995	CcSEcCtD
Alprostadil—Thrombocytopenia—Methotrexate—lymphatic system cancer	0.000297	0.00098	CcSEcCtD
Alprostadil—Skin disorder—Methotrexate—lymphatic system cancer	0.000295	0.000972	CcSEcCtD
Alprostadil—Hyperhidrosis—Methotrexate—lymphatic system cancer	0.000293	0.000968	CcSEcCtD
Alprostadil—Hypotension—Methotrexate—lymphatic system cancer	0.000283	0.000935	CcSEcCtD
Alprostadil—Dyspepsia—Methotrexate—lymphatic system cancer	0.000267	0.000881	CcSEcCtD
Alprostadil—Pain—Methotrexate—lymphatic system cancer	0.000259	0.000856	CcSEcCtD
Alprostadil—Feeling abnormal—Methotrexate—lymphatic system cancer	0.00025	0.000825	CcSEcCtD
Alprostadil—Abdominal pain—Methotrexate—lymphatic system cancer	0.00024	0.000791	CcSEcCtD
Alprostadil—Body temperature increased—Methotrexate—lymphatic system cancer	0.00024	0.000791	CcSEcCtD
Alprostadil—Asthenia—Methotrexate—lymphatic system cancer	0.000218	0.000718	CcSEcCtD
Alprostadil—Pruritus—Methotrexate—lymphatic system cancer	0.000215	0.000708	CcSEcCtD
Alprostadil—Diarrhoea—Methotrexate—lymphatic system cancer	0.000208	0.000685	CcSEcCtD
Alprostadil—Dizziness—Methotrexate—lymphatic system cancer	0.000201	0.000662	CcSEcCtD
Alprostadil—Rash—Methotrexate—lymphatic system cancer	0.000191	0.000631	CcSEcCtD
Alprostadil—Dermatitis—Methotrexate—lymphatic system cancer	0.000191	0.000631	CcSEcCtD
Alprostadil—Headache—Methotrexate—lymphatic system cancer	0.00019	0.000627	CcSEcCtD
Alprostadil—Nausea—Methotrexate—lymphatic system cancer	0.00018	0.000595	CcSEcCtD
